Julien Masliah-Planchon

10PUBLICATIONS
118CO-AUTHORS
Molecular targetsPredictive and prognostic markersEpigenetics (incl. genome methylation and epigenomics)Gene and molecular therapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 10, 2026
DNMT3B plays antagonistic roles with SMARCB1 and is a targetable vulnerability in rhabdoid tumors.

|Mar 09, 2026
Prognostic factors in adult patients with medulloblastoma.

Ytel Garcilazo-Reyes, Pierre Dal Col, Franck Bielle

|Feb 24, 2025
Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition.

Peter N Fiorica, Lisa Golmard, Jung Kim

|Dec 28, 2024
Nanopore sequencing as a cutting-edge technology for medulloblastoma classification.

Mathilde Filser, Jacob Torrejon, Kevin Merchadou

|Aug 29, 2024
Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients.

Didier Decaudin, Fariba Némati, Julien Masliah Planchon

|Aug 02, 2024
Postzygotic mosaicism of SMARCB1 variants in patients with rhabdoid tumors: A not-so-rare condition exposing to successive tumors.

Grégory Thomson, Mathilde Filser, Léa Guerrini-Rousseau

Pageof 2

Frequent Collaborators

5 joint publications

Franck Bourdeaut

4 joint publications

Olivier Delattre

3 joint publications

Mathilde Filser

2 joint publications

Grégory Thomson